THe challenge
Patients with rare cancers face poor outcomes compared to patients with common cancers. This is because progress requires data and funding, which is traditionally a challenge for rare disease research.
Our Partnership with the Broad Institute of MIT & Harvard is changing this.
““Prior to the launch of the Katie Moore Fund, there were two major barriers to progress in rare cancer research: it was impossible for patients with rare cancers at any hospital in the US to donate living samples of their cancer tissue for the creation of cell models, and in the lab, there was no proven strategy to create cell models from any rare tumor with high success rates.
With the support of the Katie Moore Foundation, we’ve overcome these two barriers.””